C12orf60 Inhibitors
The inhibition of various kinases and enzymes can lead to a cascade of effects that indirectly inhibit C12orf60. BMS-354825 (Dasatinib), which targets Src family kinases and BCR-ABL kinase, could diminish C12orf60 activity if it is associated with growth and proliferation pathways regulated by these kinases. PP2, another selective Src family kinase inhibitor, could reduce C12orf60's function if it is involved in signaling pathways influenced by Src kinase activity. Y-27632, a ROCK inhibitor, can impact C12orf60 by altering cytoskeletal dynamics and associated signaling if C12orf60's function is tied to the Rho/ROCK pathway.
Rapamycin's inhibition of mTOR could lead to decreased C12orf60 activity by reducing protein synthesis and cell proliferation, affecting C12orf60 if its function is related to these processes. Additionally, LY3214996, by selectively inhibiting ERK1/2, suppresses the MAPK/ERK pathway, potentially reducing C12orf60 activation. SP600125's inhibition of JNK could lead to decreased C12orf60 activity if C12orf60 is a downstream effector of JNK signaling. NSC23766, by inhibiting Rac1, could inhibit the activity of C12orf60 if it's involved in cell migration or actin cytoskeleton organization linked to Rac1 activity.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
A specific inhibitor of phosphoinositide 3-kinases (PI3K), LY294002 can indirectly inhibit C12orf60 by disrupting the PI3K/AKT pathway, which is crucial for many cellular survival and growth processes. If C12orf60 is part of a downstream response within this pathway, its functional activity would be decreased due to the suppression of PI3K signaling. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin inhibits mTOR (mechanistic target of rapamycin), a key kinase in the mTOR signaling pathway which integrates cellular nutrient and energy levels. By inhibiting mTOR, rapamycin could lead to a decrease in protein synthesis and cell proliferation, which could indirectly inhibit C12orf60 if its function is related to these cellular processes. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
An inhibitor of p38 MAP Kinase, SB203580 can reduce the cellular responses to stress and cytokines. If C12orf60 is involved in stress response signaling or is regulated by cytokine signaling pathways involving p38 MAPK, its activity would be decreased by the inhibition of this kinase. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is a potent and irreversible inhibitor of PI3K. By inhibiting PI3K, it disrupts the PI3K/AKT pathway, leading to reduced cellular survival and proliferation signals. If C12orf60 operates within this pathway, or is reliant on it for activation, its activity would be decreased due to the disruption caused by wortmannin. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 specifically inhibits MEK, which is part of the MAPK/ERK pathway. This inhibition prevents the activation of downstream ERK, which could result in decreased functional activity of C12orf60 if it is regulated by or involved in this pathway. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
An inhibitor of c-Jun N-terminal kinase (JNK), SP600125 can reduce the activity of transcription factors regulated by JNK, leading to changes in gene expression. If C12orf60 is a downstream effector of JNK signaling, its activity would be decreased by the inhibition of JNK. | ||||||
LY3214996 | 1951483-29-6 | sc-507299 | 5 mg | $265.00 | ||
LY3214996 is a selective ERK1/2 inhibitor. By inhibiting ERK1/2, it can suppress the MAPK/ERK signaling pathway, potentially leading to decreased activation of downstream targets. If C12orf60's activity is promoted by this pathway, inhibition of ERK1/2 would result in a reduction of C12orf60's functional activity. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $70.00 $145.00 | 51 | |
Dasatinib is a Src family kinase inhibitor, and it also inhibits BCR-ABL kinase. By targeting these kinases, Dasatinib can alter signaling pathways that regulate cell growth and proliferation. If C12orf60 is associated with these pathways or is a substrate of these kinases, its activity would be diminished due to the inhibition of Src or BCR-ABL. | ||||||
PP 2 | 172889-27-9 | sc-202769 sc-202769A | 1 mg 5 mg | $94.00 $227.00 | 30 | |
PP2 is a selective inhibitor of Src family tyrosine kinases. The inhibition of Src kinases can affect multiple signaling pathways, including those regulating cell adhesion, growth, and differentiation. If C12orf60 is involved in any of these processes and is regulated by Src kinase activity, its function would be decreased by the action of PP2. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $186.00 $707.00 | 88 | |
Y-27632 is an inhibitor of ROCK (Rho-associated protein kinase), which plays a role in actin cytoskeleton organization. If C12orf60 is involved in cellular structures or motility regulated by the Rho/ROCK pathway, its activity could be decreased due to the inhibition of ROCK, leading to alterations in cytoskeletal dynamics and associated signaling pathways. | ||||||